Biodexa Pharmaceuticals Plc – NASDAQ:BDRX
Biodexa Pharmaceuticals stock price today
Biodexa Pharmaceuticals stock price monthly change
Biodexa Pharmaceuticals stock price quarterly change
Biodexa Pharmaceuticals stock price yearly change
Biodexa Pharmaceuticals key metrics
Market Cap | 906.10M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -17.02 |
Revenue | 381K |
EBITDA | -6.45M |
Income | -7.07M |
Revenue Q/Q | -64.06% |
Revenue Y/Y | -45.49% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -1695.01% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiodexa Pharmaceuticals stock price history
Biodexa Pharmaceuticals stock forecast
Biodexa Pharmaceuticals financial statements
| Mar 2023 | 149K | -1.78M | -1197.32% |
|---|---|---|---|
| Jun 2023 | 149K | -1.78M | -1197.32% |
| Sep 2023 | 41.5K | -1.75M | -4230.12% |
| Dec 2023 | 41.5K | -1.75M | -4230.12% |
| 2027 | 3.02K | -715 | -23.68% |
|---|
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 7962000 | 2.66M | 33.45% |
|---|---|---|---|
| Jun 2023 | 7962000 | 2.66M | 33.44% |
| Sep 2023 | 10542000 | 5.86M | 55.63% |
| Dec 2023 | 10542000 | 5.86M | 55.63% |
| Mar 2023 | -1.94M | 10K | 3.12M |
|---|---|---|---|
| Jun 2023 | -1.94M | 10K | 3.12M |
| Sep 2023 | -1.47M | -142.5K | 1.98M |
| Dec 2023 | -1.47M | -142.5K | 1.98M |
Biodexa Pharmaceuticals alternative data
| Dec 2023 | 27 |
|---|---|
| Jan 2024 | 27 |
| Feb 2024 | 27 |
| Mar 2024 | 27 |
| Apr 2024 | 27 |
| May 2024 | 21 |
| Jun 2024 | 21 |
| Jul 2024 | 21 |
Biodexa Pharmaceuticals other data
-
What's the price of Biodexa Pharmaceuticals stock today?
One share of Biodexa Pharmaceuticals stock can currently be purchased for approximately $7.01.
-
When is Biodexa Pharmaceuticals's next earnings date?
Unfortunately, Biodexa Pharmaceuticals's (BDRX) next earnings date is currently unknown.
-
Does Biodexa Pharmaceuticals pay dividends?
No, Biodexa Pharmaceuticals does not pay dividends.
-
How much money does Biodexa Pharmaceuticals make?
Biodexa Pharmaceuticals has a market capitalization of 906.10M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 45.49% to 381K US dollars.
-
What is Biodexa Pharmaceuticals's stock symbol?
Biodexa Pharmaceuticals Plc is traded on the NASDAQ under the ticker symbol "BDRX".
-
What is Biodexa Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Biodexa Pharmaceuticals?
Shares of Biodexa Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Biodexa Pharmaceuticals have?
As Jul 2024, Biodexa Pharmaceuticals employs 21 workers, which is 22% less then previous quarter.
-
When Biodexa Pharmaceuticals went public?
Biodexa Pharmaceuticals Plc is publicly traded company for more then 9 years since IPO on 7 Dec 2015.
-
What is Biodexa Pharmaceuticals's official website?
The official website for Biodexa Pharmaceuticals is biodexapharma.com.
-
How can i contact Biodexa Pharmaceuticals?
Biodexa Pharmaceuticals can be reached via phone at +44 29 2048 0180.
Biodexa Pharmaceuticals company profile:
Biodexa Pharmaceuticals Plc
biodexapharma.comNASDAQ
21
Biotechnology
Healthcare
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Cardiff, CF10 4DQ
CIK: 0001643918
ISIN: US59564R7089
:
